BSc2118

10/01/2014 - "Finally, safety and efficacy of BSc2118 was evaluated in a mouse melanoma model. "
10/01/2014 - "Finally, administration of BSc2118 in a mouse melanoma model shows significant local anti-tumor effects. "
10/01/2014 - "Biodistribution and Efficacy Studies of the Proteasome Inhibitor BSc2118 in a Mouse Melanoma Model."

10/01/2015 - "Together, these findings indicate the in vitro and in vivo anti-MM activities of BSc2118 through induction of cell cycle arrest and apoptosis, as well as inhibition of tumor angiogenesis. "
10/01/2015 - "BSc2118 suppressed tumor cell growth through induction of G2/M phase arrest and induced apoptosis via activation of the apoptotic signaling cascade, in association with up-regulation of p53 and p21. "
08/01/2010 - "Taken together, BSc2118 shows significant antimyeloma activity and may be considered as a promising agent in cancer drug development."
10/01/2014 - "Finally, administration of BSc2118 in a mouse melanoma model shows significant local anti-tumor effects. "
10/01/2014 - "In our study we characterized the anti-tumor properties of the novel proteasome inhibitor BSc2118. "

08/01/2010 - "The purpose of this study was to elucidate the effects of the novel proteasome inhibitor BSc2118 on t(4;14) positive and negative multiple myeloma (MM) cells and normal peripheral blood mononuclear cells (PBMNC). "
08/01/2010 - "BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma."
10/01/2015 - "Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma."

04/01/2019 - "Thus, in our study, we used a novel fluorescent-tagged proteasome inhibitor BSc2118 to induce aggresome formation in C26 murine colon adenocarcinoma cells. "

11/01/2012 - "Single injections of BSc2118 induced long-term neuroprotection, reduced functional impairment, stabilized blood-brain barrier through decreased MMP9 activity and enhanced angioneurogenesis when given no later than 12 h post-stroke. "
11/01/2016 - "Systemic delivery of BSc2118 induced acute neuroprotection reflected by reduced infarct volume when delivered up to 9 h post-stroke. "
11/01/2012 - "Thus, the proteasome inhibitor BSc2118 is a promising new candidate for stroke therapy, which may in addition alleviate recombinant tissue-plasminogen activator-induced brain toxicity."
11/01/2012 - "BSc2118 was intrastriatally injected 12 h post-stroke in mice that had received normal saline or recombinant tissue-plasminogen activator injections during early reperfusion. "